Overview
Certolizumab pegol is a PEGylated Fab' fragment of a humanised anti-TNF-α antibody. Unlike other anti-TNF agents, it lacks an Fc region, which means it does not activate complement or cause antibody-dependent cell-mediated cytotoxicity. It is approved for Crohn's disease and is notably used in pregnancy because minimal drug crosses the placenta.
Key Uses
Moderate-to-severe Crohn's disease
Particularly suitable for use in pregnancy (minimal placental transfer)
Also approved for rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis
How It Works
Binds and neutralises TNF-α without Fc-mediated effector functions
PEGylation extends its half-life, allowing less frequent dosing
Induction: 400 mg SC at weeks 0, 2, and 4; maintenance: 400 mg SC every 4 weeks (or 200 mg every 2 weeks)
Low placental transfer makes it the preferred anti-TNF in pregnancy when treatment is needed
Safety & Self-Care
TB and hepatitis B screening required before starting
Discuss with your IMCC team if you are pregnant or planning pregnancy — certolizumab is often continued in pregnancy
Report infection signs promptly
Rotate injection sites and store pens in the refrigerator
Avoid live vaccines for infants exposed to certolizumab in utero for at least 6 months after birth
Contact Your IMCC Team
Contact your IMCC team before or during pregnancy, if you develop infection, or if symptoms worsen between doses.
Share this with someone who needs it: